Emphasizing the use of semaglutide; a significant advancement in the management of chronic kidney disease in diabetic patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Emphasizing the use of semaglutide; a significant advancement in the management of chronic kidney disease in diabetic patients

Published:2024-08-19 Issue: Volume: Page:
ISSN:1573-2584
Container-title:International Urology and Nephrology
language:en
Short-container-title:Int Urol Nephrol

Author:

Fasieh Haleema,Naeem Amna Binte,Hussain Mubashir

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11255-024-04185-4.pdf

Reference7 articles.

1. Russo MP, Grande-Ratti MF, Burgos MA, Molaro AA, Bonella MB (2023) Prevalence of diabetes, epidemiological characteristics and vascular complications. Arch Cardiol Mex 93(1):30–36

2. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease–PubMed [Internet]. [cited 2024 Aug 7]. Available: https://pubmed.ncbi.nlm.nih.gov/36651820/

3. Kommu S, Whitfield P. Semaglutide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Aug 7]. Available: http://www.ncbi.nlm.nih.gov/books/NBK603723/

4. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G et al (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 391(2):109–121

5. Safety of Semaglutide–PubMed [Internet]. [cited 2024 Aug 7]. Available: https://pubmed.ncbi.nlm.nih.gov/34305810/

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP